Edwin Miska, Director of Equities at First Investors Corporation, came to own Actavis plc (ACT) through M&A events and has seen the stock outperform due to its continued consolidation activity.
“We had very strong performance in our health care stocks. Actavis, a larger generic and branded drug manufacturer, was one of the leaders,” Miska said. “This was not the holding we bought, however. In fact, we wound up owning Actavis through M&A events.”
FOR MORE INFORMATION ON THIS INTERVIEW CLICK HERE.
Miska came to own Actavis through its acquisition of both Watson Pharmaceuticals and Warner Chilcott, and is looking forward to the company’s future M&A activity.
“They are largely a consolidation player in the specialty pharmaceutical and generic pharmaceuticals space. They recently announced another deal, as they will acquire Forest Labs (FRX), generating further earnings accretion and potential upside for us,” Miska said.
Actavis (ACT) Has Large Exposure to Generic Drugs in Alternative Dosage Forms
May 01, 2013
Rowan Companies PLC (RDC) to Benefit as Jackup Market Outperforms Floating Rig Market
February 07, 2014
HITECH Act Drives Adoption of Health Care IT Solutions
June 27, 2011
Catamaran (CTRX), Cerner (CERN) and athenahealth (ATHN) Enable HITECH Act Meaningful Use Adoption of EHR
October 24, 2012
21st Century Cures Act Likely to Accelerate Demand for Medidata Solutions Inc (MDSO)
November 03, 2015
